Medicare & Medicaid SweepBack to stories →
← Back to stories
Billing & paymentConditional reminder

Medicare to pay ASP minus 28 percent, or another set basis where ASP is unavailable, for separately payable 340B-acquired drugs at non-exempt hospitals from January 1, 2027 (pass-through drugs, vaccines and non-opioid pain relief drugs excluded); every separately paid OPPS drug line must carry modifier JG, TB or ND

In the CY 2027 Hospital Outpatient Prospective Payment System (OPPS) final rule, published November 6, 2026, CMS will pay average sales price (ASP) minus 28 percent for separately payable drugs acquired under the 340B Program at non-exempt hospitals from January 1, 2027 when ASP is available; where ASP is not available, payment is based on wholesale acquisition cost (WAC) minus 28 percent, then 64.53 percent of average wholesale price (AWP), then 100 percent of mean unit cost (MUC), then the invoice price, and certain products such as nonpass-through diagnostic radiopharmaceuticals with claims data continue to be paid on arithmetic MUC; pass-through drugs, vaccines and non-opioid pain relief drugs are excluded, and rural sole community hospitals (SCHs), children's hospitals and cancer hospitals exempt from the prospective payment system (PPS) are exempt. From the same date every separately paid OPPS drug claim line, billed under its Healthcare Common Procedure Coding System (HCPCS) code, must carry modifier JG, TB or ND.

A gloved hand steadies sealed cartons on a blue cart at a loading dock with an open truck backed in.
Illustrative artwork; not evidence of the actual people, products or events described.

Current status

The Federal Register record for the CY 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) final rule (document 2026-22739) was read on November 15, 2026: it lists no corrections and gives an effective date of January 1, 2027. No correction document for the rule appears among the CMS documents published November 8 through 15, 2026. The rule text was not re-read. The comment close date of January 4, 2027 shown in the record was not reconciled with the rule text. Court dockets were not checked for a challenge to the payment cut.

Who this affects

All hospitals paid under the OPPS, including excepted and non-excepted off-campus provider-based departments, for separately payable drugs. Payment cut applies to 340B covered entity hospitals; rural SCHs, children's hospitals and PPS-exempt cancer hospitals are exempt from the cut and report the informational modifier TB on separately payable drugs bought with a 340B discount (ND on drugs not acquired under 340B). Critical Access Hospitals (CAHs) and Rural Emergency Hospitals (REHs) are outside the OPPS.

Why it matters

This is a claim-level compliance duty for every OPPS hospital, not only 340B participants: non-340B hospitals must append ND to separately paid drug lines from January 1, 2027. Inference: 340B hospitals need line-level split-billing data (340B versus non-340B purchase) in the pharmacy and billing systems by January 1, 2027. Inference: modifier errors could produce overpayments (missing JG) or claim edits; inference: 340B hospitals face a large drug revenue cut partly offset by the 7.50 percent non-drug increase, while non-340B hospitals gain. The rule also amends 42 CFR 427.303(b)(1)(iv) so successor 340B modifiers are used to exclude 340B units from Part B inflation rebates.

Required actions

  • From January 1, 2027, report modifier JG on the same claim line as the drug HCPCS code for 340B-acquired separately payable drugs to which the payment reduction applies (non-exempt OPPS hospitals; the reduction does not reach pass-through drugs, vaccines or non-opioid pain relief drugs with status indicator K1)
  • From January 1, 2027, report modifier TB as the rule's final modifier table directs: the summary lists it for 340B-acquired drugs at rural SCHs, children's hospitals and PPS-exempt cancer hospitals and for pass-through and non-opioid pain relief drugs, and the detailed discussion ties TB to drugs bought with a 340B discount
  • From January 1, 2027, report modifier ND for all separately paid drugs not acquired through the 340B Program (all OPPS hospitals, including excepted and non-excepted off-campus provider-based departments (PBDs))

Implementation playbook

  1. Confirm the hospital's status under the 340B payment policy (subject to the reduction, or an exempt rural sole community hospital, children's hospital or PPS-exempt cancer hospital), which decides between modifiers JG and TB. Owner: Reimbursement. Due: 2026-11-30.
  2. Build and test the claim-line modifier logic so that every separately paid drug line carries JG, TB or ND, using the rule's final modifier table. Owner: Revenue Cycle, Pharmacy and IT. Due: testing complete 2026-12-15; live for dates of service from 2027-01-01 (the rule's date).
  3. Reconcile 340B accumulator and split-billing data so that 340B-acquired drugs are identified correctly at the claim line. Owner: Pharmacy 340B program. Due: 2026-12-15.
  4. Model the effect of ASP minus 28 percent, and of the alternative bases where ASP is unavailable, on 340B drug revenue against the estimated 7.50 percent increase to non-drug payments, and update the 2027 budget. Owner: Finance. Due: 2026-12-15.
  5. Check for CMS claims instructions implementing the modifiers. Owner: Compliance. Due: 2026-12-01, then weekly through January 2027.

Scope and timing

Authority status
Final
Responsible owner
Pharmacy / 340B Program (primary); Revenue Cycle; Compliance; Finance
Publication date
2026-11-06
Effective date
2027-01-01
Compliance date
2027-01-01 (modifier reporting on separately paid drug claims)
Other dates
Hospital acquisition cost survey conducted 2026-01-01 through 2026-04-07; Federal Register record lists comments_close_on 2027-01-04 (what the comment period covers not reconciled with the rule text)

Not established

Court dockets were not checked. The final modifier table and CMS claims instructions for the modifiers were not retrieved.

Earlier article: November 8, 2026 edition →

Sources

Complete edition and supplemental material

This article in the complete report →

Executive triage, source-coverage limitations, context and forward horizons remain in the complete report.

Read the entire Medicare & Medicaid Sweep report →

← Return to stories

Privacy preferences

Where enabled for this site, Cloudflare Web Analytics can send page-use and performance measurements to Cloudflare. This panel provides information and does not turn analytics on or off.

This panel stores no tracking choice and does not change your tool saves, screening, resets, reports or exports. Other sites have separate settings.

Read Privacy & Cookies